Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols



Abbas TO, Al-Naimi AR, Yakoob RA, Al-Bozom IA, Alobaidly AM. Prostate cancer metastases to the rectum: a case report. World journal of surgical oncology.May 21 2011;9:56.

Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytotherapy research: PTR.Oct 2010;24(10):1423-1432.

Abu El Maaty MA, Wolfl S. Vitamin D as a Novel Regulator of Tumor Metabolism: Insights on Potential Mechanisms and Implications for Anti-Cancer Therapy. International journal of molecular sciences. Oct 19 2017;18(10).

ACS. American Cancer Society. Chemmotherapy for prostate cancer. Available at last updated 03/11/2016. Accessed 12/08/2017.

ACS. American Cancer Society. Understanding Your Pathology Report: Prostate Cancer. Last updated 3/8/2017. Accessed 11/29/2017.

Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis.Mar 2012;33(3):644-651.

Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian journal of surgical oncology.Jun 2012;3(2):120-129.

Aghajanpour M, Nazer MR, Obeidavi Z, Akbari M, Ezati P, Kor NM. Functional foods and their role in cancer prevention and health promotion: a comprehensive review. American journal of cancer research.2017;7(4):740-769.

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, . . . Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet.Feb 25 2017;389(10071):815-822.

Ajdzanovic V, Mojic M, Maksimovic-Ivanic D, Bulatovic M, Mijatovic S, Milosevic V, Spasojevic I. Membrane fluidity, invasiveness and dynamic phenotype of metastatic prostate cancer cells after treatment with soy isoflavones. The Journal of membrane biology.Apr 2013;246(4):307-314.

Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, . . . Foster BA. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PloS one.2014;9(2):e89555.

Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D, . . . Dubeck F. Health Economic Impact and Prospective Clinical Utility of Oncotype DX(R) Genomic Prostate Score. Rev Urol.2016;18(3):123-132.

Albisinni S, Aoun F, Bellucci S, Biaou I, Limani K, Hawaux E, . . . van Velthoven R. Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis. Journal of endourology / Endourological Society. Jan 2017;31(1):14-19.

Albrecht M, Jiang W, Kumi-Diaka J, Lansky EP, Gommersall LM, Patel A, . . . Campbell MJ. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. Journal of medicinal food.Fall 2004;7(3):274-283.

Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nature reviews. Urology. Feb 2017;14(2):107-119.

Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, . . . Cheung AM. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.Oct 2013;24(10):2571-2579.

Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, . . . Mori M. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational new drugs.Apr 2015;33(2):480-489.

Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, . . . Prorok PC. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst.Jan 18 2012;104(2):125-132.

Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int.Sep 2003;92(4):375-378; discussion 378.

Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, . . . Drake CG. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical cancer research: an official journal of the American Association for Cancer Research.May 15 2017;23(10):2451-2459.

Antwi SO, Steck SE, Zhang H, Stumm L, Zhang J, Hurley TG, Hebert JR. Plasma carotenoids and tocopherols in relation to prostate-specific antigen (PSA) levels among men with biochemical recurrence of prostate cancer. Cancer epidemiology.Oct 2015;39(5):752-762.

Apte SA, Cavazos DA, Whelan KA, Degraffenried LA. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer. Nutrition and cancer.2013;65(4):556-562.

Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, . . . Galet C. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer prevention research (Philadelphia, Pa.).Dec 2011;4(12):2062-2071.

Aucoin M, Cooley K, Knee C, Fritz H, Balneaves LG, Breau R, . . . Seely D. Fish-Derived Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review. Integrative cancer therapies.Mar 2017;16(1):32-62.

Augmenix. What is SpaceOAR Hydrogel? Copyright by Augmenix, Inc. Accessed 12/28/2017.

Ayyildiz SN, Ayyildiz A. PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turkish journal of urology. Jun 2014;40(2):82-88.

Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C. Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study. Clin Med Oncol. 2007;1:73-80.

Azoury SC, Straughan DM, Shukla V. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety. Current cancer drug targets.2015;15(6):452-462.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, . . . Emberton M. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. The Lancet. Oncology.Feb 2017;18(2):181-191.

Baade PD, Youlden DR, Gardiner RA, Ferguson M, Aitken JF, Yaxley J, Chambers SK. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia. BJU Int. Dec 2012;110(11 Pt B):E712-719.

Bagheri MH, Ahlman MA, Lindenberg L, Turkbey B, Lin J, Cahid Civelek A, . . . Apolo AB. Advances in medical imaging for the diagnosis and management of common genitourinary cancers. Urologic oncology.Jul 2017;35(7):473-491.

Baguley BJ, Bolam KA, Wright ORL, Skinner TL. The Effect of Nutrition Therapy and Exercise on Cancer-Related Fatigue and Quality of Life in Men with Prostate Cancer: A Systematic Review. Nutrients.Sep 12 2017;9(9).

Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, . . . Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol.Jul 2012;62(1):55-63.

Ballon-Landa E, Parsons JK. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Current opinion in urology.Jan 2018;28(1):55-61.

Bambury RM, Rathkopf DE. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. Urologic oncology.Aug 2016;34(8):348-355.

Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM, Jr., . . . Kristal AR. Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol.Jun 2015;1(3):342-349.

Basnet A, Khullar G, Mehta R, Chittoria N. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab. Clinical genitourinary cancer.Oct 2017;15(5):e881-e884.

Baum RP, Kulkami HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med.2016;57(7):1006-1013.

Beauval JB, Cabarrou B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A, . . . Roumiguie M. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. Prostate.Jun 2017;77(8):928-933.

Bednarova S, Lindenberg ML, Vinsensia M, Zuiani C, Choyke PL, Turkbey B. Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. Transl Androl Urol. Jun 2017;6(3):413-423.

Bergin ART, Hovey E, Lloyd A, Marx G, Parente P, Rapke T, de Souza P. Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer.Sep 2017;25(9):2871-2879.

Berquin IM, Edwards IJ, Kridel SJ, Chen YQ. Polyunsaturated fatty acid metabolism in prostate cancer. Cancer metastasis reviews.Dec 2011;30(3-4):295-309.

Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, . . . Boorjian SA. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. J Urol.Jun 29 2017.

Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. JAMA.May 16 2017;317(19):1949-1950.

Bilusic M, Madan RA, Gulley JL. Immunotherapy of Prostate Cancer: Facts and Hopes. Clinical cancer research: an official journal of the American Association for Cancer Research.Jun 29 2017.

Bjurlin MA, Rosenkrantz AB, Taneja SS. MRI-fusion biopsy: the contemporary experience. Transl Androl Urol. Jun 2017;6(3):483-489.

Bjurlin MA, Wysock JS, Taneja SS. Optimization of prostate biopsy: review of technique and complications. The Urologic clinics of North America.May 2014;41(2):299-313.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, . . . Saad F. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. Jun 01 2015;21(11):2591-2600.

Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, . . . Semjonow A. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged </=65 years. BJU Int.Jan 2016;117(1):72-79.

Bonetta A, Di Pierro F. Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma. Cancer management and research.2012;4:281-286.

Bonetta A, Roviello G, Generali D, Zanotti L, Cappelletti MR, Pacifico C, Di Pierro F. Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. Research and reports in urology.2017;9:65-69.

Bosire C, Stampfer MJ, Subar AF, Park Y, Kirkpatrick SI, Chiuve SE, . . . Reedy J. Index-based dietary patterns and the risk of prostate cancer in the NIH-AARP diet and health study. Am J Epidemiol.Mar 15 2013;177(6):504-513.

Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, . . . Rosario DJ. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. Apr 2016;69(4):693-703.

Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, . . . Lawrence HJ. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology.Mar 2016;89:69-75.

Brandstedt J, Almquist M, Manjer J, Malm J. Vitamin D, PTH, and calcium in relation to survival following prostate cancer. Cancer Causes Control.May 2016;27(5):669-677.

Brauer A, Grubert LS, Roll W, Schrader AJ, Schafers M, Bogemann M, Rahbar K. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. European journal of nuclear medicine and molecular imaging.Sep 2017;44(10):1663-1670.

Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, . . . Fehr J. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PloS one.2015;10(7):e0133028.

Brawer MK. Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer. Rev Urol.2003;5 Suppl 6:S10-16.

Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, Allard WJ. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology.Sep 1998;52(3):372-378.

Broderick JM. FDA Grants Apalutamide Priority Review for Nonmetastatic CRPC. 12/21/2017. Accessed 01/08/2018.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, . . . Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Apr 20 2017;35(12):1341-1367.

Byun DJ, Cohn MR, Patel SN, Donin NM, Sosnowski R, Bjurlin MA. The Effect of Smoking on 30-Day Complications Following Radical Prostatectomy. Clinical genitourinary cancer.Apr 2017;15(2):e249-e253.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, . . . Fizazi K. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. Journal for immunotherapy of cancer.2017;5:31.

Capurso C, Vendemiale G. The Mediterranean Diet Reduces the Risk and Mortality of the Prostate Cancer: A Narrative Review. Frontiers in nutrition. 2017;4:38.

Caras RJ, Sterbis JR. Prostate cancer nomograms: a review of their use in cancer detection and treatment. Current urology reports.Mar 2014;15(3):391.

Carlsson SV, Roobol MJ. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Current opinion in urology.May 2017;27(3):198-204.

Carmody J, Olendzki B, Reed G, Andersen V, Rosenzweig P. A dietary intervention for recurrent prostate cancer after definitive primary treatment: results of a randomized pilot trial. Urology.Dec 2008;72(6):1324-1328.

CDC. Centers for Disease Control and Prevention. Prostate Cancer Risk by Age. Last updated 12/15/2015. Accessed 8/19/2017.

CDC. Centers for Disease Control and Prevention. National Hospital Discharge Survey: 2010 table, Procedures by selected patient characteristics - Number by procedure category and age. 2010. Accessed 8/29/2017.

CDC. Centers for Disease Control and Prevention. Prostate Cancer Rates by Race and Ethnicity. Last updated 6/19/2017. Accessed 8/19/2017.

Cheetham PJ, Katz AE. Diet and prostate cancer - a holistic approach to management. Archivos espanoles de urologia. Oct 2011;64(8):720-734.

Chen H, Na R, Packiam VT, Conran CA, Jiang D, Tao S, . . . Xu J. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial. Prostate.Aug 2017;77(11):1179-1186.

Chen J, Song Y, Zhang L. Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. J Nutr Sci Vitaminol (Tokyo).2013;59(3):213-223.

Chen N, Zhou Q. The evolving Gleason grading system. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. Feb 2016;28(1):58-64.

Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate Cancer Screening in a New Era of Genetics. Clinical genitourinary cancer.May 31 2017.

Christie DR, Sharpley CF, Bitsika V. Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer. Psycho-oncology.Sep 2015;24(9):1002-1011.

Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. European journal of cancer (Oxford, England: 1990).Aug 2015;51(12):1555-1569.

Cicione A, De Nunzio C, Tubaro A, Cantiello F, Manno S, Oliveira C, . . . Damiano R. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study. BMC cancer. Feb 04 2016;16:59.

Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, . . . Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis.Dec 2012;15(4):346-352.

Costa WH, Jabboure GN, Cunha IW. Urological cancer related to familial syndromes. International braz j urol: official journal of the Brazilian Society of Urology.Mar-Apr 2017;43(2):192-201.

Costello LC, Franklin RB. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Archives of biochemistry and biophysics.Dec 01 2016;611:100-112.

Counago F, Sancho G, Catala V, Hernandez D, Recio M, Montemuino S, . . . Del Cerro E. Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know. World journal of clinical oncology.Aug 10 2017;8(4):305-319.

Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, . . . Langley RE. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary clinical trials.Nov 2016;51:56-64.

Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, . . . Ward JF. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int.Jun 2017;119(6):896-904.

Cui K, Li X, Du Y, Tang X, Arai S, Geng Y, . . . Zhang T. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget.May 30 2017;8(22):36674-36684.

Curtis A, Ondracek RP, Murekeyisoni C, Kauffman E, Mohler J, Marshall J. Tobacco use and outcome in radical prostatectomy patients. Cancer Med. Apr 2017;6(4):857-864.

Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, . . . Scardino P. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British journal of cancer.Jul 28 2015;113(3):382-389.

Danciu C, Avram S, Pavel I, Ghiulai R, Dehelean C, Ersilia A, . . . Soica C. Main Isoflavones Found in Dietary Sources as Natural Anti-inflammatory Agents. Current drug targets.Nov 9 2017.

Dani H, Loeb S. The role of prostate cancer biomarkers in undiagnosed men. Current opinion in urology.May 2017;27(3):210-216.

Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, . . . Litwin MS. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer.May 15 2011;117(10):2058-2066.

Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int.Jan 2003;91(1):14-17.

Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schroder FH, . . . Rosen RC. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int.Feb 2017;119(2):216-224.

Deep G, Kumar R, Nambiar DK, Jain AK, Ramteke AM, Serkova NJ, . . . Agarwal R. Silibinin inhibits hypoxia-induced HIF-1alpha-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics. Molecular carcinogenesis.Mar 2017;56(3):833-848.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MTt, . . . Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.Dec 2008;17(12):3577-3587.

Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, . . . Vollmer RT. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology.Jul 2001;58(1):47-52.

deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H, Hackman RM. Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutrition and cancer.2010;62(8):1036-1043.

Deziel B, MacPhee J, Patel K, Catalli A, Kulka M, Neto C, . . . Hurta R. American cranberry (Vaccinium macrocarpon) extract affects human prostate cancer cell growth via cell cycle arrest by modulating expression of cell cycle regulators. Food Funct.May 2012;3(5):556-564.

Deziel BA, Patel K, Neto C, Gottschall-Pass K, Hurta RA. Proanthocyanidins from the American Cranberry (Vaccinium macrocarpon) inhibit matrix metalloproteinase-2 and matrix metalloproteinase-9 activity in human prostate cancer cells via alterations in multiple cellular signalling pathways. Journal of cellular biochemistry.Oct 15 2010;111(3):742-754.

Dickerman BA, Ahearn TU, Giovannucci E, Stampfer MJ, Nguyen PL, Mucci LA, Wilson KM. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. International journal of cancer. Journal international du cancer.Sep 01 2017;141(5):933-944.

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, . . . Dietlein M. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med.Jun 2017;58(6):947-952.

Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, . . . Mulders PF. The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. Springerplus.2016;5:653.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, . . . Wilding G. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. Sep 2015;68(3):365-371.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, . . . Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Mar 20 2016;34(9):987-1011.

Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, . . . Trpkov K. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer.Jan 15 2010;116(2):323-330.

Downer MK, Batista JL, Mucci LA, Stampfer MJ, Epstein MM, Hakansson N, . . . Andersson SO. Dairy intake in relation to prostate cancer survival. International journal of cancer. Journal international du cancer. May 01 2017;140(9):2060-2069.

Dueregger A, Heidegger I, Ofer P, Perktold B, Ramoner R, Klocker H, Eder IE. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients.Oct 21 2014;6(10):4491-4519.

Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, . . . Cathelineau X. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int.Jan 2014;113(1):56-64.

Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. European journal of immunology.May 2017;47(5):765-779.

Eapen RS, Herlemann A, Washington SL, 3rd, Cooperberg MR. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Current opinion in urology.May 2017;27(3):205-209.

Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, . . . Giesel FL. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med.Sep 2017;58(Suppl 2):67s-76s.

Eiber M, Souvatzoglou M, Maurer T, Ziegler S, Rummeny E, Schwaiger M, Beer A. Initial experience in restaging of patients with recurrent prostate cancer: Comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT. Journal of Nuclear Medicine.May 1, 2013 2013;54(supplement 2):343.

Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The Metabolic Phenotype of Prostate Cancer. Frontiers in oncology.2017;7:131.

Eisenberger M, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, . . . de Bono J. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Aug 15 2017:Jco2016721076.

El Touny LH, Banerjee PP. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer research.Apr 15 2009;69(8):3695-3703.

Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American journal of surgical pathology.Apr 2017;41(4):e1-e7.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, . . . Klein EA. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol.Mar 2016;69(3):428-435.

Epstein MM, Kasperzyk JL, Andren O, Giovannucci EL, Wolk A, Hakansson N, . . . Mucci LA. Dietary zinc and prostate cancer survival in a Swedish cohort. The American journal of clinical nutrition.Mar 2011;93(3):586-593.

Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, . . . Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol.Aug 01 2012;176(3):240-252.

Estevez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Quintela ML, . . . Macia Escalante S. Prostate cancer perspectives after chaarted: Optimizing treatment sequence. Critical reviews in oncology/hematology. Nov 2016;107:119-127.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst.Jul 03 2002;94(13):981-990.

Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? The Urologic clinics of North America.May 2014;41(2):223-228.

Fahmy O, Khairul-Asri MG, Hadi S, Gakis G, Stenzl A. The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. Urol Int.Jul 04 2017.

Feng P, Li TL, Guan ZX, Franklin RB, Costello LC. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate.Sep 01 2002;52(4):311-318.

Ferguson PJ, Kurowska EM, Freeman DJ, Chambers AF, Koropatnick J. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. Nutrition and cancer.2006;56(1):86-94.

Ferro M, Lucarelli G, Bruzzese D, Di Lorenzo G, Perdona S, Autorino R, . . . Terracciano D. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget.Mar 14 2017;8(11):18424-18434.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, . . . de Bono JS. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology.Oct 2012;13(10):983-992.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, . . . Chi KN. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med.Jul 27 2017;377(4):352-360.

Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, . . . Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate.Jun 01 2010;70(8):848-855.

Flannigan RK, Baverstock RJ. Management of post-radiation therapy complications among prostate cancer patients: A case series. Can Urol Assoc J.Sep 2014;8(9-10):E632-636.

Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nature reviews. Urology.Jan 2017;14(1):26-37.

Fong L. An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy. [Internet]. Bethesda (MD): National LIbrary of Medicine. Identifier: NCT02506114. Last updated 6/8/2017. Accessed 1/9/2018.

Franz MC, Anderle P, Burzle M, Suzuki Y, Freeman MR, Hediger MA, Kovacs G. Zinc transporters in prostate cancer. Molecular aspects of medicine.Apr-Jun 2013;34(2-3):735-741.

Freiberger C, Berneking V, Vogeli TA, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival. Radiation oncology (London, England).Jun 14 2017;12(1):98.

Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, . . . Eggener S. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol.May 05 2017.

Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, . . . Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer research.Oct 01 2005;65(19):9080-9088.

Galasso F, Giannella R, Bruni P, Giulivo R, Barbini VR, Disanto V, . . . Sepe G. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study. Archivio italiano di urologia, andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia.Mar 2010;82(1):5-9.

Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, . . . Aronson WJ. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer prevention research (Philadelphia, Pa.).Jan 2014;7(1):97-104.

Galvao DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP, . . . Newton RU. Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nature reviews. Urology.May 2016;13(5):258-265.

Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, Briganti A. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol.Aug 2017;72(2):289-292.

Garcia-Barreras S, Sanchez-Salas R, Sivaraman A, Barret E, Secin F, Nunes-Silva I, . . . Cathelineau X. Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes. J Urol.Aug 17 2017.

Garisto JD, Klotz L. Active Surveillance for Prostate Cancer: How to Do It Right. Oncology (Williston Park, N.Y.).May 15 2017;31(5):333-340, 345.

Geybels MS, Neuhouser ML, Wright JL, Stott-Miller M, Stanford JL. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control.Nov 2013;24(11):1947-1954.

Gilbert DC, Duong T, Kynaston HG, Alhasso AA, Cafferty FH, Rosen SD, . . . Abel PD. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int.May 2017;119(5):667-675.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, . . . Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol.Jun 24 2017.

Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutrition and cancer. 2010;62(7):919-930.

Golbari NM, Katz AE. Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review. Current urology reports.Aug 2017;18(8):63.

Goldenberg MG, Goldenberg L, Grantcharov TP. Surgeon Performance Predicts Early Continence After Robot-Assisted Radical Prostatectomy. Journal of endourology / Endourological Society. Sep 2017;31(9):858-863.

Golla V, Kaplan AL. Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer. Current urology reports.Jul 2017;18(7):49.

Gonzalez A, Peters U, Lampe JW, White E. Zinc intake from supplements and diet and prostate cancer. Nutrition and cancer.2009;61(2):206-215.

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, . . . de Bono JS. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov.Apr 27 2017.

Gorawara-Bhat R, O'Muircheartaigh S, Mohile S, Dale W. Patients' perceptions and attitudes on recurrent prostate cancer and hormone therapy: Qualitative comparison between decision-aid and control groups. Journal of geriatric oncology.Jun 08 2017.

Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagnostic pathology.Mar 09 2016;11:25.

Goyal NK, Kumar A, Trivedi S, Dwivedi US, Singh PB. Surgical complications of radical retropubic prostatectomy: A single institutional experience of seven years. Indian journal of urology: IJU: journal of the Urological Society of India.Oct 2007;23(4):369-371.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, . . . Beer TM. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget.Aug 16 2016;7(33):52810-52817.

Gu Z, Suburu J, Chen H, Chen YQ. Mechanisms of omega-3 polyunsaturated fatty acids in prostate cancer prevention. Biomed Res Int.2013;2013:824563.

Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis.2003;6(4):301-304.

Gulley JL. Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer. [Internet]. Bethesda (MD): National Library of Medicine. Identifier: NCT02933255. Last updated 10/19/2017. Accessed 1/9/2018.

Gupta D, Salmane C, Slovin S, Steingart RM. Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer. Current treatment options in cardiovascular medicine. Aug 2017;19(8):61.

Hackett GI. Testosterone Replacement Therapy and Mortality in Older Men. Drug safety: an international journal of medical toxicology and drug experience.Feb 2016;39(2):117-130.

Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare tumors.Dec 31 2010;2(4):e65.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, . . . Neal DE. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. Oct 13 2016;375(15):1415-1424.

Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, . . . Van Veldhuizen P. Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. PloS one.2013;8(7):e68331.

Hamilton K, Bennett NC, Purdie G, Herst PM. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo controlled pilot study. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer.Jan 2015;23(1):95-102.

Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, . . . Michalski J. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. International journal of radiation oncology, biology, physics.Apr 01 2017;97(5):976-985.

Hannoun-Levi JM. Brachytherapy for prostate cancer: Present and future. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique.Aug 25 2017.

Hart NH, Galvao DA, Newton RU. Exercise medicine for advanced prostate cancer. Current opinion in supportive and palliative care.Sep 2017;11(3):247-257.

Hatakeyama S, Yoneyama T, Tobisawa Y, Ohyama C. Recent progress and perspectives on prostate cancer biomarkers. Int J Clin Oncol.Apr 2017;22(2):214-221.

Hebert JR, Hurley TG, Harmon BE, Heiney S, Hebert CJ, Steck SE. A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. Cancer epidemiology.Apr 2012;36(2):e128-136.

Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, . . . Gulley JL. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget.Oct 18 2016;7(42):69014-69023.

Hegemann M, Bedke J, Stenzl A, Todenhofer T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Therapeutic advances in urology.Mar-Apr 2017;9(3-4):81-88.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, . . . Catalona WJ. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human genetics.Apr 2015;134(4):439-450.

Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol.May 2016;27(5):755-757.

Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, . . . Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate.Apr 01 2015;75(5):550-559.

Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, . . . Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol.Jul 2003;44(1):8-15; discussion 15-16.

Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M, Cueto S, Rodriguez-Gonzalez P, Garcia-Alonso JI, . . . Sainz RM. Melatonin Decreases Glucose Metabolism in Prostate Cancer Cells: A (13)C Stable Isotope-Resolved Metabolomic Study. International journal of molecular sciences.Jul 26 2017;18(8).

Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo, Brazil).2012;67(6):661-668.

Ho T, Howard LE, Vidal AC, Gerber L, Moreira D, McKeever M, . . . Freedland SJ. Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clinical cancer research: an official journal of the American Association for Cancer Research.Oct 15 2014;20(20):5331-5338.

Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, . . . Castle EP. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clinical genitourinary cancer.Apr 2017;15(2):196-202.e191.

Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. Journal of general internal medicine.Oct 2000;15(10):694-701.

Holmes-Rovner M, Srikanth A, Henry SG, Langford A, Rovner DR, Fagerlin A. Decision aid use during post-biopsy consultations for localized prostate cancer. Health expectations: an international journal of public participation in health care and health policy.Sep 07 2017.

Holmes JA, Bensen JT, Mohler JL, Song L, Mishel MH, Chen RC. Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort. Cancer.Jan 01 2017;123(1):138-143.

Howard LE, Moreira D, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, . . . Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int.Mar 28 2017.

Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. Jan 2013;68(1):56-61.

Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, . . . Lee YF. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-dihydroxyvitamin D3. Am J Pathol.Feb 2011;178(2):872-880.

Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol.Mar 2004;17(3):292-306.

Hvid T, Lindegaard B, Winding K, Iversen P, Brasso K, Solomon TP, . . . Hojman P. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients. Cancer Causes Control.Feb 2016;27(2):165-174.

Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, . . . Horie S. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate.Jul 01 2010;70(10):1127-1133.

Israeli RS. Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol.Spring 2008;10(2):99-110.

Ito K, Fujizuka Y, Ishikura K, Cook B. Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen. Int J Clin Oncol.Oct 2014;19(5):782-792.

Jackson CL, Dreaden TM, Theobald LK, Tran NM, Beal TL, Eid M, . . . Mohnen D. Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. Glycobiology.Aug 2007;17(8):805-819.

Jacob SA, Khan TM, Lee LH. The Effect of Green Tea Consumption on Prostate Cancer Risk and Progression: A Systematic Review. Nutrition and cancer.Apr 2017;69(3):353-364.

Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Nov 20 2014;32(33):3716-3722.

Jambor I, Bostrom PJ, Taimen P, Syvanen K, Kahkonen E, Kallajoki M, . . . Aronen HJ. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of magnetic resonance imaging: JMRI. Oct 2017;46(4):1089-1095.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, . . . Sydes MR. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med.Jul 27 2017;377(4):338-351.

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, . . . Parmar MK. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet.Mar 19 2016;387(10024):1163-1177.

Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, . . . Schrag D. Physician visits prior to treatment for clinically localized prostate cancer. Archives of internal medicine.Mar 08 2010;170(5):440-450.

Jiang J, Eliaz I, Sliva D. Synergistic and additive effects of modified citrus pectin with two polybotanical compounds, in the suppression of invasive behavior of human breast and prostate cancer cells. Integrative cancer therapies.Mar 2013;12(2):145-152.

Jones MR, Joshu CE, Kanarek N, Navas-Acien A, Richardson KA, Platz EA. Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999-2010. Preventing chronic disease.Apr 14 2016;13:E51.

Jones RA, Hollen PJ, Wenzel J, Weiss G, Song D, Sims T, Petroni G. Understanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid. Cancer nursing.Nov 01 2016.

Jones TA, Chin J, McLeod D, Barkin J, Pantuck A, Marks LS. High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial. J Urol.Jun 23 2017.

Jones TA, Radtke JP, Hadaschik B, Marks LS. Optimizing safety and accuracy of prostate biopsy. Current opinion in urology.Sep 2016;26(5):472-480.

Junghans RP, Ma Q, Rathore R, Gomes EM, Bais AJ, Lo AS, . . . Cohen SI. Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate. Oct 2016;76(14):1257-1270.

Kajla P, Sharma A, Sood DR. Flaxseed-a potential functional food source. Journal of food science and technology.Apr 2015;52(4):1857-1871.

Kanthabalan A, Peters M, Van Vulpen M, McCartan N, Hindley RG, Emara A, . . . Ahmed HU. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. BJU Int.Aug 2017;120(2):246-256.

Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, . . . Crevenna R. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer.Sep 2017;25(9):2953-2968.

Keizman D. Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA. [Internet]. Bethesda (MD): National LIbrary of Medicine. Identifier: NCT01681823. Last updated 5/30/2017. Accessed 9/15/2017.

Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA.Jun 22 2011;305(24):2548-2555.

Kim HJ, Phak JH, Kim WC. Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma. Radiation oncology journal.Dec 2016;34(4):260-264.

Kim SP, Gross CP, Nguyen PL, Smaldone MC, Thompson RH, Shah ND, . . . Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis.Jun 2014;17(2):163-169.

Kim TH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. Scand J Urol.Feb 2017;51(1):27-32.

Kim YS, Rhim H, Choi MJ, Lim HK, Choi D. High-intensity focused ultrasound therapy: an overview for radiologists. Korean journal of radiology.Jul-Aug 2008;9(4):291-302.

Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst.Aug 01 2007;99(15):1200-1209.

Kishan AU, King CR. Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. Seminars in radiation oncology.Jul 2017;27(3):268-278.

Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol.Jan 2013;31(1):71-75.

Koch MO, Cho JS, Kaimakliotis HZ, Cheng L, Sangale Z, Brawer M, . . . Stone S. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer biomarkers: section A of Disease markers.Jun 07 2016;17(1):83-88.

Koskela K, Palmgren JE, Heikkila J, Virsunen H, Sailas L, Auvinen P, . . . Kataja V. Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience. Acta oncologica (Stockholm, Sweden).Jul 2017;56(7):978-983.

Ku JY, Lee CH, Lee JZ, Ha HK. Comparison of functional outcomes between laparoscopic radical prostatectomy and robot-assisted laparoscopic radical prostatectomy: a propensity score-matched comparison study. Asia Pac J Clin Oncol.Jun 2017;13(3):212-218.

Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, . . . Wood DP, Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2001;10(8):861-868.

Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, . . . Baum RP. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. Oct 2016;57(Suppl 3):97s-104s.

Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, . . . Krischer JP. Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy. Clinical medicine. Urology [electronic resource].Apr 16 2008;1:1-14.

Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, . . . Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer prevention research (Philadelphia, Pa.).Oct 2015;8(10):879-887.

Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, . . . Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget.Oct 25 2016;7(43):70794-70802.

Kwan W, Duncan G, Van Patten C, Liu M, Lim J. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutrition and cancer.2010;62(2):198-207.

Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, . . . Bourke L. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol.Jul 27 2017.

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, . . . Karlsen SJ. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutrition and cancer.2011;63(6):889-898.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, . . . Bonanni B. A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. Cancer prevention research (Philadelphia, Pa.).Jan 2016;9(1):89-95.

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, . . . Ottini L. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Jul 10 2017;35(20):2240-2250.

Leclere L, Cutsem PV, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. Frontiers in Pharmacology.2013;4.

Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, Barocas DA. Recent changes in prostate cancer screening practices and prostate cancer epidemiology. J Urol.May 25 2017.

Lee SH, Seo HJ, Lee NR, Son SK, Kim DK, Rha KH. Robot-assisted radical prostatectomy has lower biochemical recurrence than laparoscopic radical prostatectomy: Systematic review and meta-analysis. Investigative and clinical urology.May 2017;58(3):152-163.

Lee TK, Breau RH, Mallick R, Eapen L. A systematic review of expanded prostate cancer index composite (EPIC) quality of life after surgery or radiation treatment. The Canadian journal of urology.Feb 2015;22(1):7599-7606.

Lee YH, Kwak J, Choi HK, Choi KC, Kim S, Lee J, . . . Yoon HG. EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int J Mol Med.Jul 2012;30(1):69-74.

Legisi L, DeSa E, Qureshi MN. Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population. American health & drug benefits.Dec 2016;9(9):497-502.

Lesinski GB, Reville PK, Mace TA, Young GS, Ahn-Jarvis J, Thomas-Ahner J, . . . Clinton SK. Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. Cancer prevention research (Philadelphia, Pa.).Nov 2015;8(11):1036-1044.

Levesque C, Nelson PS. Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harbor perspectives in medicine. May 10 2017.

Li Y, Ahmad A, Kong D, Bao B, Sarkar FH. Recent progress on nutraceutical research in prostate cancer. Cancer metastasis reviews.Sep 2014;33(2-3):629-640.

Lian WQ, Luo F, Song XL, Lu YJ, Zhao SC. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. Med Sci Monit.Jul 01 2015;21:1902-1910.

Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, . . . Aronson WJ. Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate.Oct 2016;76(14):1293-1302.

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, . . . Inderberg EM. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother.Jul 2017;66(7):891-901.

Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC medicine.Jan 08 2015;13:3.

Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA.Jun 27 2017;317(24):2532-2542.

Liu B, Mao Q, Cao M, Xie L. Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis. Int J Urol.Feb 2012;19(2):134-141.

Liu Q, Tong D, Liu G, Xu J, Do K, Geary K, . . . Jiang J. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT. Cell death & disease.Aug 24 2017;8(8):e3007.

Lloyd JC, Masko EM, Wu C, Keenan MM, Pilla DM, Aronson WJ, . . . Freedland SJ. Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression. Prostate Cancer Prostatic Dis. Dec 2013;16(4):285-291.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, . . . Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol.Jun 2014;65(6):1046-1055.

Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Therapeutic advances in urology.Apr 2014;6(2):74-77.

Loughlin KR. PSA velocity: a systematic review of clinical applications. Urologic oncology.Nov 2014;32(8):1116-1125.

Lowrance WT, Scardino PT. Predictive models for newly diagnosed prostate cancer patients. Rev Urol.Summer 2009;11(3):117-126.

Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate.Feb 2014;74(3):286-296.

Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An Overview. Oncology reviews.Mar 03 2017;11(1):321.

Madan RA. Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer. [Internet]. Bethesda (MD): National Library of Medicine. Identifier: NCT02649855. Last updated 11/24/2017. Accessed 1/9/2018.

Madan RA, Gulley JL. Prostate cancer immunotherapy: the path forward. Current opinion in supportive and palliative care.Sep 2017;11(3):225-230.

Magnuson WJ, Mahal A, Yu JB. Emerging Technologies and Techniques in Radiation Therapy. Seminars in radiation oncology.Jan 2017;27(1):34-42.

Mahammedi H, Planchat E, Pouget M, Durando X, Cure H, Guy L, . . . Eymard JC. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology.2016;90(2):69-78.

Malatesta M, Mannello F, Luchetti F, Marcheggiani F, Condemi L, Papa S, Gazzanelli G. Prostate-specific antigen synthesis and secretion by human placenta: a physiological kallikrein source during pregnancy. The Journal of clinical endocrinology and metabolism.Jan 2000;85(1):317-321.

Malietzis G, Monzon L, Hand J, Wasan H, Leen E, Abel M, . . . Abel P. High-intensity focused ultrasound: advances in technology and experimental trials support enhanced utility of focused ultrasound surgery in oncology. The British journal of radiology.Apr 2013;86(1024):20130044.

Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. Oct 11 2005;102(41):14813-14818.

Maluf FC, Smaletz O, Herchenhorn D. Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo, Brazil).2012;67(4):389-394.

Mandl SJ, Rountree RB, Dela Cruz TB, Foy SP, Cote JJ, Gordon EJ, . . . Franzusoff A. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. Journal for immunotherapy of cancer.2014;2(1):34.

Manivannan E, Amawi H, Hussein N, Karthikeyan C, Fetcenko A, Narayana Moorthy NSH, . . . Tiwari AK. Design and discovery of silybin analogues as antiproliferative compounds using a ring disjunctive - Based, natural product lead optimization approach. European journal of medicinal chemistry.Jun 16 2017;133:365-378.

Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Current opinion in urology.Jan 2013;23(1):43-50.

Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, . . . Gattoni-Celli S. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. The Journal of clinical endocrinology and metabolism.Jul 2012;97(7):2315-2324.

Martignano F, Rossi L, Maugeri A, Galla V, Conteduca V, De Giorgi U, . . . Schepisi G. Urinary RNA-based biomarkers for prostate cancer detection. Clinica chimica acta; international journal of clinical chemistry.Aug 12 2017;473:96-105.

Masterson TA, Bianco FJ, Jr., Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, . . . Scardino PT. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol.Apr 2006;175(4):1320-1324; discussion 1324-1325.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, . . . de Bono JS. DNA Repair in Prostate Cancer: Biology and Clinical Implications. European urology.Mar 2017;71(3):417-425.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, . . . de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med.Oct 29 2015;373(18):1697-1708.

Mayo Clinic. Prostate Cancer: Symptoms & causes. 2/15/2018. Accessed 2/15/2018.

Mayo Clinic. Prostatitis: Symptoms & causes. 11/23/2016. Accessed 8/17/2017.

Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A, Gonzalez-Menendez P, Cepas V, . . . Sainz RM. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. Journal of pineal research.Jan 2017;62(1).

McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer prevention research (Philadelphia, Pa.). Jul 2009;2(7):673-682.

McLeod DG. Success and failure of single-modality treatment for early prostate cancer. Rev Urol.2004;6 Suppl 2:S13-19.

McMahon GC, Brown GA, Mueller TJ. Utilization of individualized prostate cancer and genomic biomarkers for the practicing urologist. Rev Urol. 2017;19(2):97-105.

Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, . . . Taneja SS. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. Mar 2016;69(3):512-517.

Metmark Genetics. [Press Release]. Metmark Receives Positive Medicare Final Coverage Decision for ProMark. 8/30/2016. Accessed 12/28/2017.

Mondul AM, Weinstein SJ, Moy KA, Mannisto S, Albanes D. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.Apr 2016;25(4):665-669.

Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, . . . Taplin ME. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research.Mar 15 2016;22(6):1356-1363.

Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urologic oncology.Feb 2017;35(2):59-68.

Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J, Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. The Journal of steroid biochemistry and molecular biology. Jul 2010;121(1-2):368-371.

Moreel X, Allaire J, Leger C, Caron A, Labonte ME, Lamarche B, . . . Fradet V. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer prevention research (Philadelphia, Pa.).Jul 2014;7(7):766-776.

Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D, Jr., Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol.Apr 2011;185(4):1256-1260.

Moukayed M, Grant WB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms. Reviews in endocrine & metabolic disorders.Jun 2017;18(2):167-182.

Moul JW. Hormone naive prostate cancer: predicting and maximizing response intervals. Asian journal of andrology.Nov-Dec 2015;17(6):929-935; discussion 933.

Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med.Jul 17 2012;157(2):120-134.

Mucci LA, Kantoff PW. Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer? Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Oct 10 2017;35(29):3272-3274.

Nambiar DK, Rajamani P, Deep G, Jain AK, Agarwal R, Singh RP. Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling. Molecular cancer therapeutics.Dec 2015;14(12):2722-2734.

Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, . . . Fanti S. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. European journal of nuclear medicine and molecular imaging.Aug 2016;43(9):1601-1610.

National Guideline C. ACR Appropriateness Criteria: prostate cancer--pretreatment detection, surveillance, and staging. 2016.

NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. 2/21/2017a. Accessed 8/3/2017.

NCCN. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Prostate Cancer. Copyright 2016a. Accessed 8/2/2017.

NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Version 2. 2017b.

NCCN. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Prostate Cancer. In: Network NCC, ed. Fort Washington, PA: National Comprehensive Cancer Network Foundation; 2016b.

NCCN. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Prostate Cancer. In: Network NCC, ed. Fort Washington, PA: National Comprehensive Cancer Network Foundation; 2016c.

NCI. National Cancer Institute. Radiation Therapy for Cancer. 6/30/2010. Accessed 6/1/2015.

NCI. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Last updated 10/4/2017d. Accessed 2/14/2018.

NCI. National Cancer Institute. FDA approval for abiraterone acetate. Available at Last updated 07/01/2013. Accessed 12/07/2017.

NCI. National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men. Accessed 10/27/2017a.

NCI. National Cancer Institute. CAR T cells: Engineering patients' immune cells to treat their cancers. Last updated 08/31/2017b. Accessed 12/09/2017.

NCI. PDQ Prostate Cancer Prevention. Last updated 8/17/2017c.

NCI. PDQ Prostate Cancer Screening. Last updated 2/9/2018a. Accessed 2/14/2018.

NCI. PDQ Prostate Cancer Treatment. Last updated 2/6/2018b. Accessed 2/14/2018.

Nelson R. FDA Approves First HIFU Device for Prostate Tissue Ablation. Medscape. 10/22/2015. Accessed 2/15/2018.

Nelson WG, DeMarzo AM, Yegnasubramanian S. The Diet as a Cause of Human Prostate Cancer. Cancer treatment and research.2014;159:51-68.

Newsom-Davis TE, Kenny LM, Ngan S, King J, Waxman J. The promiscuous receptor. BJU Int.Nov 2009;104(9):1204-1207.

Nguyen JY, Major JM, Knott CJ, Freeman KM, Downs TM, Saxe GA. Adoption of a plant-based diet by patients with recurrent prostate cancer. Integrative cancer therapies.Sep 2006;5(3):214-223.

Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, . . . Klein EA. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol.May 18 2017.

Nguyen TM, Pastuszak AW. Testosterone Therapy Among Prostate Cancer Survivors. Sexual medicine reviews.Oct 2016;4(4):376-388.

NLM. U.S. National Library of Medicine. PubMed Health [online]. Adrenal Glands: About the Adrenal Glands. Accessed 11/29/2017.

Nordstrom T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, . . . Paris PL. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate.Mar 2016;76(4):339-348.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, . . . McDonnell DP. Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. The Journal of clinical investigation.Jun 01 2017;127(6):2326-2338.

Novio S, Cartea ME, Soengas P, Freire-Garabal M, Nunez-Iglesias MJ. Effects of Brassicaceae Isothiocyanates on Prostate Cancer. Molecules.May 12 2016;21(5).

O'Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, . . . Scher HI. A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology.Apr 2017;102:164-172.

Onik G, Barrie K, Miessau M, Bostwick D, Vaughan D, Brady J, Budd W. Long-Term Results of Optimized Focal Therapy for Prostate Cancer: Average 10-Year Follow-Up in 70 Patients. Journal of Men's Health.2014;11(2):64-74.

Orom H, Biddle C, Underwood W, 3rd, Nelson CJ, Homish DL. What Is a "Good" Treatment Decision? Decisional Control, Knowledge, Treatment Decision Making, and Quality of Life in Men with Clinically Localized Prostate Cancer. Medical decision making: an international journal of the Society for Medical Decision Making.Aug 2016;36(6):714-725.

Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL. Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes. J Urol.Oct 2016;196(4):1082-1089.

Ottanelli S. Prevention and treatment of bone fragility in cancer patient. Clin Cases Miner Bone Metab. May-Aug 2015;12(2):116-129.

Packer JR, Maitland NJ. The molecular and cellular origin of human prostate cancer. Biochimica et biophysica acta.Jun 2016;1863(6 Pt A):1238-1260.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, . . . Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis.Mar 2013;16(1):50-55.

Pandolfi F, Franza L, Mandolini C, Conti P. Immune Modulation by Vitamin D: Special Emphasis on Its Role in Prevention and Treatment of Cancer. Clin Ther.May 2017;39(5):884-893.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, . . . Belldegrun A. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research.Jul 01 2006;12(13):4018-4026.

Paroni R, Terraneo L, Bonomini F, Finati E, Virgili E, Bianciardi P, . . . Samaja M. Antitumour activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signalling. Journal of pineal research.Aug 2014;57(1):43-52.

Partin AW, W VANC, Trock BJ, Epstein JI, L VANN. CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Transactions of the American Clinical and Climatological Association.2016;127:313-327.

Pastuszak AW, Rodriguez KM, Nguyen TM, Khera M. Testosterone therapy and prostate cancer. Transl Androl Urol.Dec 2016;5(6):909-920.

Patel SA, Hoffman-Censits J. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. OncoTargetsand therapy.2017;10:4089-4098.

Patrikidou A, Uccello M, Tree A, Parker C, Attard G, Eeles R, . . . Reid A. Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)).Oct 2017;29(10):e174-e175.

Paur I, Lilleby W, Bohn SK, Hulander E, Klein W, Vlatkovic L, . . . Blomhoff R. Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical nutrition (Edinburgh, Scotland).Jun 2017;36(3):672-679.

Payton S. Prostate cancer: New PSA screening guideline faces widespread opposition. Nature reviews. Urology. Jun 05 2012;9(7):351.

Pdq Integrative A, Complementary Therapies Editorial B. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ(R)): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2017.

Peabody JW, DeMaria LM, Tamondong-Lachica D, Florentino J, Czarina Acelajado M, Ouenes O, . . . Burgon T. Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial. BMC urology.Jul 03 2017;17(1):51.

Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol.Jun 2017;35(6):867-874.

Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC cancer.May 11 2008;8:132.

Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tjonneland A, Olsen A, . . . Travis RC. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC medicine.Jul 13 2017;15(1):115.

Perez-Cornago A, Travis RC, Appleby PN, Tsilidis KK, Tjonneland A, Olsen A, . . . Key TJ. Fruit and vegetable intake and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). International journal of cancer. Journal international du cancer.Jul 15 2017;141(2):287-297.

Petrunak EM, Rogers SA, Aube J, Scott EE. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1. Drug Metab Dispos.Jun 2017;45(6):635-645.

Peyromaure M, Fulla Y, Debre B, Dinh-Xuan AT. Pro PSA : a "pro cancer" form of PSA? Med Hypotheses.2005;64(1):92-95.

Pharmacutical Technology. FDA grants fast-track status for Innocrin's seviteronel to treat metastatic CRPC. Copyright 2017. Accessed 11/29/2017.

Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, . . . Raz A. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst.Mar 01 1995;87(5):348-353.

Pollard ME, Hobbs AR, Kwon YS, Katsigeorgis M, Lavery HJ, Levinson A, . . . Jazayeri SB. Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score. Oncology research and treatment. 2017;40(9):508-514.

Pollock PA, Ludgate A, Wassersug RJ. In 2124, half of all men can count on developing prostate cancer. Current oncology (Toronto, Ont.).Feb 2015;22(1):10-12.

Ponholzer A, Popper N, Breitenecker F, Schmid HP, Albrecht W, Loidl W, . . . Rauchenwald M. Proposal for a standardized PSA doubling-time calculation. Anticancer research.May 2010;30(5):1633-1636.

Popovic LS, Matovina-Brko G, Popovic M. Checkpoint inhibitors in the treatment of urological malignancies. ESMO open.2017;2(2):e000165.

Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, . . . De Luca S. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naive Patients with Suspected Prostate Cancer. Eur Urol.Aug 2017;72(2):282-288.

Pounis G, Tabolacci C, Costanzo S, Cordella M, Bonaccio M, Rago L, . . . Facchiano F. Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models. International journal of cancer. Journal international du cancer.Jul 01 2017;141(1):72-82.

Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Therapeutic advances in medical oncology.May 2017;9(5):307-318.

Punnen S, Pavan N, Parekh DJ. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol.2015;17(1):3-13.

Rabiau N, Kossai M, Braud M, Chalabi N, Satih S, Bignon YJ, Bernard-Gallon DJ. Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer epidemiology.Apr 2010;34(2):200-206.

Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, . . . Hillman GG. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. International journal of cancer. Journal international du cancer.Jun 01 2007;120(11):2491-2498.

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, . . . Krause BJ. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med.Jan 2017;58(1):85-90.

Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. PARP Inhibitors in Prostate Cancer. Current treatment options in oncology.Jun 2017;18(6):37.

Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. International journal of molecular sciences. Apr 17 2017;18(4).

Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene.Apr 06 2000;19(15):1924-1932.

Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. International journal of cancer. Journal international du cancer. Jul 01 2012;131(1):201-210.

Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, . . . Pourmand G. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol.Dec 2015;68(6):949-956.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol.Sep 2017;72(3):411-423.

Rivera M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, Cubano LA, Zou J, . . . Boukli NM. Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells. PloS one.2017;12(6):e0179587.

Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D, . . . Dakubo GD. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis.Jun 2010;13(2):126-131.

Rodgers L, Peer CJ, Figg WD. Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biol Ther. May 05 2017:1-3.

Ross AE, D'Amico AV, Freedland SJ. Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis.Mar 2016;19(1):1-6.

Roth AJ, Weinberger MI, Nelson CJ. Prostate cancer: psychosocial implications and management. Future oncology (London, England).Aug 2008;4(4):561-568.

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, . . . Gillessen S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol.Sep 2014;66(3):468-474.

Rubio-Briones J, Casanova J, Martinez F, Dominguez-Escrig JL, Fernandez-Serra A, Dumont R, . . . Lopez-Guerrero JA. PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme. Actas urologicas espanolas. Jun 2017;41(5):300-308.

Rundle A, Wang Y, Sadasivan S, Chitale DA, Gupta NS, Tang D, Rybicki BA. Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk. Prostate.Jun 2017;77(9):949-954.

Russo GI, Regis F, Castelli T, Favilla V, Privitera S, Giardina R, . . . Morgia G. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer. Clinical genitourinary cancer. Aug 2017;15(4):429-439.e421.

Ruxton C. Health benefits of omega-3 fatty acids. Nursing standard (Royal College of Nursing (Great Britain): 1987).Aug 11-17 2004;18(48):38-42.

Rycaj K, Li H, Zhou J, Chen X, Tang DG. Cellular determinants and microenvironmental regulation of prostate cancer metastasis. Semin Cancer Biol.Jun 2017;44:83-97.

Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cellular oncology (Dordrecht).Apr 2016;39(2):97-106.

Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. Advances in experimental medicine and biology.2015;867:93-114.

Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, . . . Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol.May 18 2017.

Sarmento-Cabral A, F LL, Gahete MD, Castano JP, Luque RM. Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways. Mol Cancer Res.Jul 2017;15(7):862-874.

Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, . . . Heber D. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. International journal of oncology.Feb 2008;32(2):475-480.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, . . . Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. The Lancet. Oncology.Jun 2014;15(7):738-746.

Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Current opinion in oncology.May 2014;26(3):259-264.

Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, . . . Eto M. Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. Japanese journal of clinical oncology.May 01 2017;47(5):453-457.

Saxe GA, Hebert JR, Carmody JF, Kabat-Zinn J, Rosenzweig PH, Jarzobski D, . . . Blute RD. Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer? J Urol.Dec 2001;166(6):2202-2207.

Sayour EJ, Mitchell DA. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res.2017;2017:3145742.

Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, . . . De Giorgi U. Immunotherapy for Prostate Cancer: Where We Are Headed. International journal of molecular sciences. Dec 5 2017;18(12).

Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, . . . Ubel PA. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Medical decision making: an international journal of the Society for Medical Decision Making.Jan 2017;37(1):56-69.

Schjenken JE, Robertson SA. Seminal Fluid Signalling in the Female Reproductive Tract: Implications for Reproductive Success and Offspring Health. Advances in experimental medicine and biology.2015;868:127-158.

Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget.Apr 07 2017.

Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, . . . Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. Journal of agricultural and food chemistry.Sep 19 2007;55(19):7732-7737.

Siddiqui IA, Asim M, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology.Apr 2011;25(4):1198-1207.

Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, . . . Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integrative cancer therapies.Jan 2014;13(1):46-53.

Silvestri I, Cattarino S, Giantulli S, Nazzari C, Collalti G, Sciarra A. A Perspective of Immunotherapy for Prostate Cancer. Cancers.Jul 07 2016;8(7).

Singh-Gupta V, Zhang H, Yunker CK, Ahmad Z, Zwier D, Sarkar FH, Hillman GG. Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharmaceutical research.Jun 2010;27(6):1115-1127.

Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate.Jul 01 2002;52(2):106-122.

Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, . . . Thibodeau SN. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet.Mar 2003;72(3):759-762.

Small EJ. Prostate Cancer. In: Goldman LS, A.I., ed. Goldman-Cecil Medicine. Philadelphia: Elsevier Health Sciences; 2015.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, . . . Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Jul 01 2006;24(19):3089-3094.

Smith CJ, Dorsey TH, Tang W, Jordan SV, Loffredo CA, Ambs S. Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Jun 2017;26(6):845-853.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, . . . Rathkopf DE. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol.Dec 2016;70(6):963-970.

Sobota AE. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J Urol.May 1984;131(5):1013-1016.

Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, . . . Dennison A. The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European journal of cancer (Oxford, England: 1990).Aug 2009;45(12):2077-2086.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, . . . Feng FY. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Jun 20 2017;35(18):1991-1998.

Srinivas S, Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer research.Sep 2009;29(9):3605-3610.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, . . . Lilja H. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. Eur Urol.Aug 2015;68(2):207-213.

Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int.Oct 2015;116(4):596-603.

Stewart GD, Van Neste L, Delvenne P, Delree P, Delga A, McNeill SA, . . . Harrison DJ. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol.Mar 2013;189(3):1110-1116.

Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the Management of Prostate Cancer. Surgical oncology clinics of North America.Jul 2017;26(3):491-513.

Stone L. Prostate cancer: Light, camera, action - photodynamic therapy for low-risk disease. Nature reviews. Urology. Mar 2017;14(3):134.

Story EN, Kopec RE, Schwartz SJ, Harris GK. An update on the health effects of tomato lycopene. Annual review of food science and technology.2010;1:189-210.

Strittmatter F, Stieber P, Nagel D, Fullhase C, Walther S, Stief CG, Waidelich R. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage? European journal of medical research.Oct 10 2011;16(10):445-450.

Student V, Vidlar A, Bouchal J, Vrbkova J, Kolar Z, Kral M, . . . Vostalova J. Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.Dec 2016;160(4):559-565.

Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, . . . Feldman D. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. International journal of cancer. Journal international du cancer.May 01 2009;124(9):2050-2059.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, . . . DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. Aug 20 2015;373(8):737-746.

Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, . . . Galvao DA. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial. Eur Urol.Aug 2017;72(2):293-299.

Tabayoyong W, Abouassaly R. Prostate Cancer Screening and the Associated Controversy. The Surgical clinics of North America.Oct 2015;95(5):1023-1039.

Taborelli M, Polesel J, Parpinel M, Stocco C, Birri S, Serraino D, Zucchetto A. Fruit and vegetables consumption is directly associated to survival after prostate cancer. Mol Nutr Food Res. Apr 2017;61(4).

Tai SY, Huang SP, Bao BY, Wu MT. Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study. Sci Rep.Jul 08 2016;6:29606.

Takagi M, Demizu Y, Terashima K, Fujii O, Jin D, Niwa Y, . . . Okimoto T. Long-term outcomes in patients treated with proton therapy for localized prostate cancer. Cancer Med.Sep 06 2017.

Tang B, Han CT, Gan HL, Zhang GM, Zhang CZ, Yang WY, . . . Ye DW. Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort. Prostate.Jun 2017;77(9):984-989.

Teply BA, Antonarakis ES. Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes.Jun 2016;23(3):279-290.

Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic advances in medical oncology.Aug 2017;9(8):565-573.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, . . . Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med.May 27 2004;350(22):2239-2246.

Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, Van Hemelrijck M, . . . Stattin P. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. Eur Urol.Jul 12 2017.

Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, . . . Wikstrom P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PloS one.Dec 03 2010;5(12):e14175.

Tosoian JJ, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, . . . Ross AE. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU Int.May 08 2017.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, . . . Ross AE. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis.Jun 2017;20(2):228-233.

Tosoian JJ, Loeb S. Radical retropubic prostatectomy: comparison of the open and robotic approaches for treatment of prostate cancer. Rev Urol.2012;14(1-2):20-27.

Traboulsi SL, Saad F. The role of bone-targeted therapies for prostate cancer in 2017. Current opinion in supportive and palliative care.Sep 2017;11(3):216-224.

Tran HN, Li Y, Udaltsova N, Armstrong MA, Friedman GD, Klatsky AL. Risk of cancer in Asian Americans: a Kaiser Permanente cohort study. Cancer Causes Control.Oct 2016;27(10):1197-1207.

USPSTF. Draft Recommendation Statement: Prostate Cancer. Screening 4/2017. Accessed 8/22/2017.

USPSTF. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med.Aug 05 2008;149(3):185-191.

Vaidyanathan R, Mishra VC. Chronic prostatitis: Current concepts. Indian journal of urology: IJU:journal of the Urological Society of India.Jan 2008;24(1):22-27.

Vaknin Y, Hadas R, Schafferman D, Murkhovsky L, Bashan N. The potential of milk thistle (Silybum marianum L.), an Israeli native, as a source of edible sprouts rich in antioxidants. International journal of food sciences and nutrition.Jun 2008;59(4):339-346.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, . . . Schalken JA. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol.Nov 2016;70(5):740-748.

Vazquez-Salas RA, Torres-Sanchez L, Lopez-Carrillo L, Romero-Martinez M, Manzanilla-Garcia HA, Cruz-Ortiz CH, . . . Moreno-Alcazar O. History of gonorrhea and prostate cancer in a population-based case-control study in Mexico. Cancer epidemiology.Feb 2016;40:95-101.

Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology.Mar 2014;83(3):592-596.

Vidal AC, Freedland SJ. Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping. Eur Urol.Jul 2017;72(1):78-83.

Vieweg J. Immunotherapy for advanced prostate cancer. Rev Urol.2007;9 Suppl 1:S29-38.

Virgo KS, Basch E, Loblaw DA, Oliver TK, Rumble RB, Carducci MA, . . . Singer EA. Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.Jun 10 2017;35(17):1952-1964.

Voltaggio L, Cimino-Mathews A, Bishop JA, Argani P, Cuda JD, Epstein JI, . . . Montgomery EA. Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. CA: a cancer journal for clinicians.Sep 2016;66(5):408-436.

Vue B, Chen QH. The Potential of Flavonolignans in Prostate Cancer Management. Current medicinal chemistry.2016;23(34):3925-3950.

Vue B, Zhang X, Lee T, Nair N, Zhang S, Chen G, . . . Chen QH. 5- or/and 20-O-alkyl-2,3-dehydrosilybins: Synthesis and biological profiles on prostate cancer cell models. Bioorganic & medicinal chemistry.Sep 01 2017;25(17):4845-4854.

Wadosky KM, Koochekpour S. Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. International journal of biological sciences. 2016;12(4):409-426.

Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, . . . Vieth R. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. The Journal of clinical endocrinology and metabolism.Apr 2013;98(4):1498-1507.

Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, . . . Nam RK. Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. Eur Urol.Jun 10 2017.

Wang A, Wang S, Zhu C, Huang H, Wu L, Wan X, . . . Zhao H. Coffee and cancer risk: A meta-analysis of prospective observational studies. Sci Rep.Sep 26 2016;6:33711.

Wang FB, Chen R, Ren SC, Shi XL, Zhu YS, Zhang W, . . . Sun YH. Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. Asian journal of andrology.Mar-Apr 2017;19(2):238-243.

Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Molecular and cellular endocrinology.Apr 30 2004;219(1-2):171-180.

Wang Q, Li YF, Jiang J, Zhang Y, Liu XD, Li K. The establishment and evaluation of a new model for the prediction of prostate cancer. Medicine.Mar 2017;96(11):e6138.

Wang YC, Chung CH, Chen JH, Chiang MH, Ti Y, Tsao CH, . . . Chang FY. Gonorrhea infection increases the risk of prostate cancer in Asian population: a nationwide population-based cohort study. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology.May 2017;36(5):813-821.

Watson GW, Beaver LM, Williams DE, Dashwood RH, Ho E. Phytochemicals from Cruciferous Vegetables, Epigenetics, and Prostate Cancer Prevention. The AAPS journal.2013;15(4):951-961.

Watson MJ, George AK, Maruf M, Frye TP, Muthigi A, Kongnyuy M, . . . Pinto PA. Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future oncology (London, England). Nov 2016;12(21):2417-2430.

Weh KM, Clarke J, Kresty LA. Cranberries and Cancer: An Update of Preclinical Studies Evaluating the Cancer Inhibitory Potential of Cranberry and Cranberry Derived Constituents. Antioxidants (Basel, Switzerland).Aug 18 2016;5(3).

Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis.Jun 20 2017.

Wells TS, Bukowinski AT, Smith TC, Smith B, Dennis LK, Chu LK, . . . Ryan MA. Racial differences in prostate cancer risk remain among US servicemen with equal access to care. Prostate.May 15 2010;70(7):727-734.

Whitburn J, Edwards CM, Sooriakumaran P. Metformin and Prostate Cancer: a New Role for an Old Drug. Current urology reports.Jun 2017;18(6):46.

Wilczynski CA, L. Testosterone effects on the prostate gland: Review of the pathophysiology and considerations in prostate cancer. J Fam Med Dis Prev.2015;1(004).

Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, . . . Mucci LA. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst.Jun 08 2011;103(11):876-884.

Wilson KM, Mucci LA, Drake BF, Preston MA, Stampfer MJ, Giovannucci E, Kibel AS. Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer prevention research (Philadelphia, Pa.).Dec 2016;9(12):933-941.

Wilt TJ, Dahm P. PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice. Journal of the National Comprehensive Cancer Network: JNCCN.Dec 2015;13(12):1566-1574.

Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, . . . Brawer MK. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. The New England journal of medicine.Jul 13 2017;377(2):132-142.

Wojno KJ, Costa FJ, Cornell RJ, Small JD, Pasin E, Van Criekinge W, . . . Van Neste L. Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. American health & drug benefits.May 2014;7(3):129-134.

Wolf F, Gaisberger C, Ziegler I, Krenn E, Scherer P, Hruby S, . . . Sedlmayer F. Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol.Aug 2015;116(2):221-225.

Woodrum DA, Kawashima A, Gorny KR, Mynderse LA. Prostate cancer: state of the art imaging and focal treatment. Clinical radiology.Aug 2017;72(8):665-679.

Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol.Dec 2009;182(6):2702-2707.

Xi SC, Siu SW, Fong SW, Shiu SY. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate.Jan 01 2001;46(1):52-61.

Xie B, Zhang G, Wang X, Xu X. Body mass index and incidence of nonaggressive and aggressive prostate cancer: a dose-response meta-analysis of cohort studies. Oncotarget.Nov 14 2017;8(57):97584-97592.

Xie DD, Chen YH, Xu S, Zhang C, Wang DM, Wang H, . . . Yu DX. Low vitamin D status is associated with inflammation in patients with prostate cancer. Oncotarget.Mar 28 2017;8(13):22076-22085.

Xu J, Janisse J, Ruterbusch JJ, Ager J, Liu J, Holmes-Rovner M, Schwartz KL. Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer. Annals of family medicine.May 2016;14(3):208-214.

Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integrative cancer therapies.Jun 2010;9(2):197-203.

Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, . . . Uemura H. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. Eur Urol.Jul 2016;70(1):35-41.

Yu S, Jiang Y, Wan F, Wu J, Gao Z, Liu D. Immortalized Cancer-associated Fibroblasts Promote Prostate Cancer Carcinogenesis, Proliferation and Invasion. Anticancer research.Aug 2017;37(8):4311-4318.

Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis. Medicine.Jul 2017;96(27):e7368.

Zappala SM, Dong Y, Linder V, Reeve M, Sjoberg DD, Mathur V, . . . Steiner M. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. International journal of clinical practice.Jun 2017;71(6).

Zardawi I, Chong P. Metastatic Prostate Cancer to the Urethra Masquerading as Urothelial Carcinoma. Urology case reports. Jul 2016;7:33-36.

Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y. Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Frontiers in oncology.2013;3:312.

Zhang S, Hu H, Wang L, Liu F, Pan S. Preparation and prebiotic potential of pectin oligosaccharides obtained from citrus peel pectin. Food chemistry.Apr 1 2018;244:232-237.

Zhang T, Zhang L, Zhang T, Fan J, Wu K, Guan Z, . . . Guo P. Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo. Radiation research.Jun 2014;181(6):641-649.

Zhou CK, Daugherty SE, Liao LM, Freedman ND, Abnet CC, Pfeiffer R, Cook MB. Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts. Cancer prevention research (Philadelphia, Pa.).Jul 2017;10(7):410-420.

Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst.Feb 2014;106(2):djt430.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, . . . Rosato A. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PloS one.2014;9(10):e109427.